<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01808690</url>
  </required_header>
  <id_info>
    <org_study_id>12-1528</org_study_id>
    <secondary_id>R56DK078645</secondary_id>
    <nct_id>NCT01808690</nct_id>
  </id_info>
  <brief_title>EMERALD: Effects of Metformin on Cardiovascular Function in Adolescents With Type 1 Diabetes</brief_title>
  <acronym>EMERALD</acronym>
  <official_title>Effects of Metformin on Cardiovascular Function in Adolescents With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes is increasingly common among youth, forecasting early complications. Type 1 (T1D)
      cause early heart disease, shortening lifespan despite modern improvements in control of
      blood sugars and other risk factors for heart disease. Poor insulin action, otherwise known
      as insulin resistance (IR), is the main factor causing heart disease in type 2 diabetes
      (T2D), but the cause of increased heart disease in T1D is unclear. IR may contribute to heart
      disease in T1D as in T2D, as the investigators and others have found the presence of IR in
      T1D. Much less is known about IR in T1D, but a better understanding of its role in T1D is
      critical to understanding causes of heart disease in T1D. The investigators long-term goal is
      to understand the early causes of heart disease in diabetes so that we can prevent it. The
      investigators unique initial findings suggest that even reasonably well-controlled, normal
      weight, T1D youth are IR. The IR appears directly related to the heart, blood vessel, and
      exercise defects, but in a pattern that appears very different from T2D. The goals of this
      study are to determine the unique heart, blood vessel and insulin sensitivity abnormalities
      in T1D youth, and determine whether metformin improves these abnormalities. A clear
      understanding of these factors will help determine the causes, and what treatments could help
      each abnormality.

      Hypothesis 1: Metformin will improve insulin function and mitochondrial function in T1D.

      Hypothesis 2: Metformin will improve vascular and cardiac function in T1D.

      All measures will be performed twice, before and after a 3-month randomized,
      placebo-controlled design where subjects are randomized to either metformin or placebo. The
      independent impact of insulin action as well as glucose levels, BMI, T1D duration, and gender
      on baseline outcomes and the impact of changes in insulin action, glucose levels and BMI on
      response to metformin will also be examined to help customize future strategies to prevent
      heart disease in T1D. This study will advance the field by providing new information about
      the role of poor insulin action in the heart disease of T1D, and whether improving insulin
      action in T1D is helpful. If a focus on directly improving insulin action in T1D youth is
      supported by our studies, the clinical approach to T1D management may significantly change.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">December 2, 2016</completion_date>
  <primary_completion_date type="Actual">December 2, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Insulin Sensitivity</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>Hypothesis 1: Metformin will improve insulin function in Type 1 Diabetes. Insulin function will be measured using a euglycemic-hyperinsulinemic clamp procedure at both baseline and after 3 months of treatment. A clamp measures insulin sensitivity. A higher number indicates a better outcome; a lower number indicates a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in ADP Time Constant</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>Hypothesis 1b: Metformin will improve mitochondrial function in Type 1 Diabetes. 31Phosphorus magnetic resonance spectroscopy (MRS) was used before, during, and after 90 seconds of near-maximal isometric exercise of the calf muscle for post-exercise muscle mitochondrial function. ADP time constant is the time for conversion of ADP → ATP and is a measure of muscle mitochondrial health (energy metabolism).
A faster recovery is a better outcome; a slower recovery is a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pulse Wave Velocity (PWV)</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>Hypothesis 2a: Metformin will improve central vascular function in Type 1 Diabetes via pulse wave velocity (PWV) by MRI. PWV is a measure of central arterial stiffness.
A lower value indicates a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Central Arterial Intimal Medial Thickness (cIMT)</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>Hypothesis 2a: Metformin will improve central vascular function in Type 1 Diabetes via central arterial intimal medial (cIMT) thickness by carotid ultrasound. cIMT is a measure used to diagnose the extent of carotid atherosclerotic vascular disease. The test measures the thickness of the inner two layers of the carotid artery—the intima and media.
A lower result is a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cardiac Function by Echocardiogram</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>Hypothesis 2b: Metformin will improve cardiac function in Type 1 Diabetes by echocardiogram.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Aortic Wall Sheer Stress (WSS)</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>Hypothesis 2a: Metformin will improve central vascular function in Type 1 Diabetes via Aortic Wall Sheer Stress (WSS) by MRI. WSS is a measure of central arterial stiffness.
A lower value indicates a better outcome.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Brachial Artery Distensibility</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>Hypothesis 2a: Metformin will improve peripheral arterial stiffness in Type 1 Diabetes via Dynapulse.
Peripheral arterial stiffness is measured by the distensibility of the arterial wall. Increased arterial stiffness results from reduced elasticity of the arterial wall.
A higher result is a better outcome.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to metformin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adolescents 12-21 years of age with type 1 diabetes (defined as having positive
             antibodies as well as insulin requirement)

          2. Willing to consent for participation in study

          3. Body Mass Index (BMI) &gt;5% on growth charts

        Exclusion Criteria:

          1. Current use of medications known to affect insulin sensitivity: oral glucocorticoids
             within 10 days, atypical antipsychotics, immunosuppressant agents, metformin or
             thiazolidinediones.

          2. Currently pregnant or breastfeeding women

          3. Use of a thiazolidinedione within 12 weeks

          4. Severe illness or Diabetic Ketoacidosis within 60 days

          5. Macroalbuminuria

          6. Hemoglobin A1c &gt; 12%

          7. Weight &gt; 136.4 kg or &lt; 42 kg, BMI &lt; 5%

          8. Creatinine &gt; 1.2

          9. Hemoglobin &lt; 9

         10. Major psychiatric or developmental disorder limiting informed consent

         11. Implanted metal devices

         12. Inability to tolerate ≥500mg twice a day of metformin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristen Nadeau, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado/Children's Hospital Colorado</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Colorado and University of Colorado Denver Health Sciences Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 6, 2013</study_first_submitted>
  <study_first_submitted_qc>March 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2013</study_first_posted>
  <results_first_submitted>January 9, 2020</results_first_submitted>
  <results_first_submitted_qc>January 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 5, 2020</results_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adolescent</keyword>
  <keyword>Youth</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Insulin Resistance</keyword>
  <keyword>Cardiovascular</keyword>
  <keyword>Metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 9, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT01808690/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Three (3) enrolled participants decided against participation in the study before randomization occurred.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Metformin</title>
          <description>Metformin will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to placebo.
Metformin</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to metformin.
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metformin</title>
          <description>Metformin will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to placebo.
Metformin</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to metformin.
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.3" spread="2.3"/>
                    <measurement group_id="B2" value="15.9" spread="2.7"/>
                    <measurement group_id="B3" value="16.6" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Insulin Sensitivity</title>
        <description>Hypothesis 1: Metformin will improve insulin function in Type 1 Diabetes. Insulin function will be measured using a euglycemic-hyperinsulinemic clamp procedure at both baseline and after 3 months of treatment. A clamp measures insulin sensitivity. A higher number indicates a better outcome; a lower number indicates a worse outcome.</description>
        <time_frame>Baseline, Month 3</time_frame>
        <population>Metformin group: 1 participant lost to follow-up, 1 IV access problem Placebo group: 2 lost to follow-up, 2 IV access problems</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Metformin will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to placebo.
Metformin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to metformin.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin Sensitivity</title>
          <description>Hypothesis 1: Metformin will improve insulin function in Type 1 Diabetes. Insulin function will be measured using a euglycemic-hyperinsulinemic clamp procedure at both baseline and after 3 months of treatment. A clamp measures insulin sensitivity. A higher number indicates a better outcome; a lower number indicates a worse outcome.</description>
          <population>Metformin group: 1 participant lost to follow-up, 1 IV access problem Placebo group: 2 lost to follow-up, 2 IV access problems</population>
          <units>(mg/kg/min)/(insulin)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" spread="3.2"/>
                    <measurement group_id="O2" value="-2.4" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Insulin function was defined as M/I (mg/kg/min)/(insulin). Power calculations were based on data from a small study in youth with poorly controlled T1DM, which reported a significant increase in M/I in the 11 participants treated with Metformin. On the basis of the effect size reported in that study, a sample size of 25 per group and an alpha of 0.05 provided us with 93% power to detect a difference of 1 SD in the primary outcome of M/I.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>Threshold for statistical significance P=0.05</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>We also fitted multivariable models, which included sex, pubertal status, change in BMI, and baseline M/I.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in ADP Time Constant</title>
        <description>Hypothesis 1b: Metformin will improve mitochondrial function in Type 1 Diabetes. 31Phosphorus magnetic resonance spectroscopy (MRS) was used before, during, and after 90 seconds of near-maximal isometric exercise of the calf muscle for post-exercise muscle mitochondrial function. ADP time constant is the time for conversion of ADP → ATP and is a measure of muscle mitochondrial health (energy metabolism).
A faster recovery is a better outcome; a slower recovery is a worse outcome.</description>
        <time_frame>Baseline, Month 3</time_frame>
        <population>22 participants had both pre/post MRS data</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Metformin will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to placebo.
Metformin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to metformin.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ADP Time Constant</title>
          <description>Hypothesis 1b: Metformin will improve mitochondrial function in Type 1 Diabetes. 31Phosphorus magnetic resonance spectroscopy (MRS) was used before, during, and after 90 seconds of near-maximal isometric exercise of the calf muscle for post-exercise muscle mitochondrial function. ADP time constant is the time for conversion of ADP → ATP and is a measure of muscle mitochondrial health (energy metabolism).
A faster recovery is a better outcome; a slower recovery is a worse outcome.</description>
          <population>22 participants had both pre/post MRS data</population>
          <units>seconds (s)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" lower_limit="-5.62" upper_limit="7.72"/>
                    <measurement group_id="O2" value="-0.47" lower_limit="-1.55" upper_limit="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.46</p_value>
            <p_value_desc>Threshold for statistical significance P=0.05</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>Adjusted for the baseline value of the variable, sex, age, change in VO2peak, change in insulin sensitivity, and treatment condition.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pulse Wave Velocity (PWV)</title>
        <description>Hypothesis 2a: Metformin will improve central vascular function in Type 1 Diabetes via pulse wave velocity (PWV) by MRI. PWV is a measure of central arterial stiffness.
A lower value indicates a better outcome.</description>
        <time_frame>Baseline, Month 3</time_frame>
        <population>Number of participants analyzed differs from participant flow numbers because the institution's MRI scanner was unavailable during replacement.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Metformin will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to placebo.
Metformin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to metformin.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pulse Wave Velocity (PWV)</title>
          <description>Hypothesis 2a: Metformin will improve central vascular function in Type 1 Diabetes via pulse wave velocity (PWV) by MRI. PWV is a measure of central arterial stiffness.
A lower value indicates a better outcome.</description>
          <population>Number of participants analyzed differs from participant flow numbers because the institution's MRI scanner was unavailable during replacement.</population>
          <units>m/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="1.2"/>
                    <measurement group_id="O2" value="4.1" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.04</p_value>
            <p_value_desc>Threshold for statistical significance P=0.05</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>We also fitted mutlivariable models, which included changed in SBP, change in BMI, and change in M/I.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Central Arterial Intimal Medial Thickness (cIMT)</title>
        <description>Hypothesis 2a: Metformin will improve central vascular function in Type 1 Diabetes via central arterial intimal medial (cIMT) thickness by carotid ultrasound. cIMT is a measure used to diagnose the extent of carotid atherosclerotic vascular disease. The test measures the thickness of the inner two layers of the carotid artery—the intima and media.
A lower result is a better outcome.</description>
        <time_frame>Baseline, Month 3</time_frame>
        <population>Metformin: 1 lost to follow-up Placebo: 2 lost to follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Metformin will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to placebo.
Metformin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to metformin.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Central Arterial Intimal Medial Thickness (cIMT)</title>
          <description>Hypothesis 2a: Metformin will improve central vascular function in Type 1 Diabetes via central arterial intimal medial (cIMT) thickness by carotid ultrasound. cIMT is a measure used to diagnose the extent of carotid atherosclerotic vascular disease. The test measures the thickness of the inner two layers of the carotid artery—the intima and media.
A lower result is a better outcome.</description>
          <population>Metformin: 1 lost to follow-up Placebo: 2 lost to follow-up</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.01"/>
                    <measurement group_id="O2" value="0.00" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.04</p_value>
            <p_value_desc>Threshold for significance P=0.05</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>We also fitted mutlivariable models, which included changed in systolic blood pressure, change in BMI, and change in M/I.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cardiac Function by Echocardiogram</title>
        <description>Hypothesis 2b: Metformin will improve cardiac function in Type 1 Diabetes by echocardiogram.</description>
        <time_frame>Baseline, Month 3</time_frame>
        <posting_date>06/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Aortic Wall Sheer Stress (WSS)</title>
        <description>Hypothesis 2a: Metformin will improve central vascular function in Type 1 Diabetes via Aortic Wall Sheer Stress (WSS) by MRI. WSS is a measure of central arterial stiffness.
A lower value indicates a better outcome.</description>
        <time_frame>Baseline, Month 3</time_frame>
        <population>Number of participants analyzed differs from participant flow numbers because the institution's MRI scanner was unavailable during replacement.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Metformin will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to placebo.
Metformin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to metformin.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Aortic Wall Sheer Stress (WSS)</title>
          <description>Hypothesis 2a: Metformin will improve central vascular function in Type 1 Diabetes via Aortic Wall Sheer Stress (WSS) by MRI. WSS is a measure of central arterial stiffness.
A lower value indicates a better outcome.</description>
          <population>Number of participants analyzed differs from participant flow numbers because the institution's MRI scanner was unavailable during replacement.</population>
          <units>dyne/cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.4"/>
                    <measurement group_id="O2" value="1.5" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <p_value_desc>Threshold for statistical significance P=0.05</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>We also fitted mutlivariable models, which included changed in SBP, change in BMI, and change in M/I.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Brachial Artery Distensibility</title>
        <description>Hypothesis 2a: Metformin will improve peripheral arterial stiffness in Type 1 Diabetes via Dynapulse.
Peripheral arterial stiffness is measured by the distensibility of the arterial wall. Increased arterial stiffness results from reduced elasticity of the arterial wall.
A higher result is a better outcome.</description>
        <time_frame>Baseline, Month 3</time_frame>
        <population>Metformin: 1 lost to follow-up Placebo: 2 lost to follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Metformin will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to placebo.
Metformin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to metformin.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Brachial Artery Distensibility</title>
          <description>Hypothesis 2a: Metformin will improve peripheral arterial stiffness in Type 1 Diabetes via Dynapulse.
Peripheral arterial stiffness is measured by the distensibility of the arterial wall. Increased arterial stiffness results from reduced elasticity of the arterial wall.
A higher result is a better outcome.</description>
          <population>Metformin: 1 lost to follow-up Placebo: 2 lost to follow-up</population>
          <units>%/mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.19"/>
                    <measurement group_id="O2" value="0.16" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8</p_value>
            <p_value_desc>Threshold for significance P=0.05</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>We also fitted mutlivariable models, which included changed in systolic blood pressure, change in BMI, and change in M/I.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Metformin</title>
          <description>Metformin will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to placebo.
Metformin</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to metformin.
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Side Effects</sub_title>
                <description>nausea, diarrhea, reduced appetite, stomach pain</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Results may not apply to prepubertal youth. Treatment duration limited to 3 months. MRI unavailable during scanner replacement. Lacked measure to monitor BGs during vascular assessments. Not all females studied in traditional follicular phase.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Kristen J Nadeau</name_or_title>
      <organization>University of Colorado Denver/Children's Hospital Colorado</organization>
      <phone>720-777-2855</phone>
      <email>Kristen.Nadeau@childrenscolorado.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

